EGFR and non-small cell lung carcinoma: In addition, the ADAURA clinical trial has revealed that the use of adjuvant Osimertinib (a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI)) was associated with prolongation of disease-free benefit, reduction of the risk of local and distant recurrence, and efficiency in EGFR-mutated NSCLC, as compared to placebo [29,30].